Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lucid DiagnosticsLUCD +1.68%13 Cash-to-Debt is 1.04 as of Mar. 2026, which is 52% below its 10-year median of 2.18. GuruFocus rates LUCD with a GF Score™ of 13/100 and a GF Value™ of $0.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 58.78% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lucid Diagnostics's cash to debt ratio for the quarter that ended in Mar. 2026 was 1.04.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lucid Diagnosticscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Lucid Diagnostics's Cash-to-Debt or its related term are showing as below:
LUCD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72 Med: 2.18 Max: No Debt
Current: 1.04
During the past 7 years, Lucid Diagnostics's highest Cash to Debt Ratio was No Debt. The lowest was 0.72. And the median was 2.18.
LUCD's Cash-to-Debt is ranked worse than 58.78% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.69
vs LUCD: 1.04
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Lucid Diagnostics Cash-to-Debt Related Terms
Lucid Diagnostics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Lucid Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Cash-to-Debt of 1.04 as of Mar. 2026. This is 52% below median its historical median of 2.18. Over the past decade, Lucid Diagnostics' Cash-to-Debt has ranged from 0.72 to 10,000.00. According to the industry distribution chart, Lucid Diagnostics ranks #499 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 58.8%.
Is Lucid Diagnostics' Cash-to-Debt too high?
Lucid Diagnostics' current Cash-to-Debt of 1.04 is 52% below median its 10-year median of 2.18. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.69. Lucid Diagnostics' value of 1.04 is 38.5% below this industry median. Based on the distribution chart, Lucid Diagnostics ranks #499 out of 849 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Lucid Diagnostics has a GF Score™ of 13/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Cash-to-Debt compare to QTRX and QSI?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #499 out of 849 companies for Cash-to-Debt. This places Lucid Diagnostics in the lower half of its industry. The industry median Cash-to-Debt is 1.69. Lucid Diagnostics' value of 1.04 is 38.5% below this benchmark. Historically, Lucid Diagnostics' own Cash-to-Debt has ranged from 0.72 to 10,000.00 over the past decade. While the company's 10-year median is 2.18 vs. the industry median of 1.69, Lucid Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.69, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current Cash-to-Debt of 1.04 is 38.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Cash-to-Debt is 1.04, which is 52% below median its own 10-year median of 2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.83, compared to a current price of $0.98 — trading 17.7% above its estimated fair value. The current Cash-to-Debt is 1.04, which is 52% below median its 10-year median of 2.18 and 38.5% below the Medical Devices & Instruments industry median of 1.69. Lucid Diagnostics' overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Cash-to-Debt is 1.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $0.98 is trading 17.7% above its estimated GF Value™ of $0.83.
GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.
Key valuation signals for LUCD:
Cash-to-Debt: 1.04 (52% below median its 10-year median of 2.18)
GF Value™: $0.83 vs. price of $0.98 (17.7% above fair value)
Industry Position: 38.5% below the Medical Devices & Instruments median (#499 of 849)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
13GF Score
Get the complete analysis for LUCD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
